The Effect of Concurrent Radiochemotherapy on Pulmonary Function Tests: Can Radiation Pneumonitis be Predicted?

The aim of the present study was to evaluate the extent of change in pulmonary function tests (PFTs) inearly and late term after concurrent radiochemotherapy (RCT) and whether the baseline PFTs or percentages of changes in PFTs after RCT would predict radiation pneumonitis (RP) after RCT in locallyadvanced non-small cell lung cancer (NSCLC).METHODSPatients with stage III NSCLC who received RCT between January 2008 and December 2014 were evaluated retrospectively with respect to patients, tumor, and treatment characteristics; PFT parametersbefore RCT; 1, 6, and 12 months after RCT; response rates; progression-free survival (PFS); and 5-yearoverall survival (OS). PFT parameters at 1, 6, and 12 months after RCT were compared with the samepatients’ baseline values. RP was assessed both clinically and radiologically.RESULTSA total of 61 patients were analyzed in the study. Median follow-up was 20 (4–116) months, and PFS was 14(2–122) months. Five-year OS was 18%. All PFT parameters declined after RCT, but only decreases in forcedexpiratory volume in 1 second at 6 and 12 months and in diffusion capacity of the lung for carbon monoxide(DLCO) at 6 months were found to be statistically significant. None of the baseline PFT parameters wasfound to be predictive of RP except the baseline DLCO; patients who had a baseline DLCO value 75% (71%–95%) (p=0.023).CONCLUSIONThere has been prominent and persistent decrease in PFT after RCT. However, the clinical outcome ofthis finding has to be evaluated. Further prospective studies with larger scales are needed to verify thepredictive value of baseline DLCO on the development of RP

PDF

___

1. Sause W, Kolesar P, Taylor S IV, Johnson D, Livingston R, Komaki R, et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 2000;117(2):358–64.
2. Cox JD. Are the results of RTOG 0617 mysterious? Int J Radiat Oncol Biol Phys 2012;82(3):1042–4.
3. Cerfolio RJ, Talati A, Bryant AS. Changes in pulmonary function tests after neoadjuvant therapy predict postoperative complications. Ann Thorac Surg 2009;88(3):930–5; discussion 935–6.
4. Semrau S, Klautke G, Fietkau R. Baseline cardiopulmonary function as an independent prognostic factor for survival of inoperable non-small-cell lung cancer after concurrent chemoradiotherapy: a single-center analysis of 161 cases. Int J Radiat Oncol Biol Phys 2011;79(1):96–104.
5. Torre-Bouscoulet L, Muñoz-Montaño WR, MartínezBriseño D, Lozano-Ruiz FJ, Fernández-Plata R, BeckMagaña JA, et al. Abnormal pulmonary function tests predict the development of radiation-induced pneumonitis in advanced non-small cell lung Cancer. Respir Res 2018;19(1):72.
6. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995;31(5):1341–6.
7. Borst GR, De Jaeger K, Belderbos JS, Burgers SA, Lebesque JV. Pulmonary function changes after radiotherapy in non-small-cell lung cancer patients with long-term disease-free survival. Int J Radiat Oncol Biol Phys 2005;62(3):639–44.
8. Gopal R, Starkschall G, Tucker SL, Cox JD, Liao Z, Hanus M, et al. Effects of radiotherapy and chemotherapy on lung function in patients with non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2003;56(1):114–20.
9. Takeda S, Funakoshi Y, Kadota Y, Koma M, Maeda H, Kawamura S, et al. Fall in diffusing capacity associated with induction therapy for lung cancer: a predictor of postoperative complication? Ann Thorac Surg 2006;82(1):232–6.
10.Kong FM, Wang S. Nondosimetric risk factors for radiation-induced lung toxicity. Semin Radiat Oncol 2015;25(2):100–9.
11.Wang J, Cao J, Yuan S, Ji W, Arenberg D, Dai J, et al. Poor baseline pulmonary function may not increase the risk of radiation-induced lung toxicity. Int J Radiat Oncol Biol Phys 2013;85(3):798–804.
12.Dang J, Li G, Zang S, Zhang S, Yao L. Risk and predictors for early radiation pneumonitis in patients with stage III non-small cell lung cancer treated with concurrent or sequential chemoradiotherapy. Radiat Oncol 2014;9:172.
13.Palma DA, Senan S, Tsujino K, Barriger RB, Rengan R, Moreno M, et al. Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis. Int J Radiat Oncol Biol Phys 2013;85(2):444–50.
14.Vogelius IR, Bentzen SM. A literature-based metaanalysis of clinical risk factors for development of radiation induced pneumonitis. Acta Oncol 2012;51(8):975–83.
15.Robnett TJ, Machtay M, Vines EF, McKenna MG, Algazy KM, McKenna WG. Factors predicting severe radiation pneumonitis in patients receiving definitive chemoradiation for lung cancer. Int J Radiat Oncol Biol Phys 2000;48(1):89–94.
16.Dehing-Oberije C, De Ruysscher D, van Baardwijk A, Yu S, Rao B, Lambin P. The importance of patient characteristics for the prediction of radiation-induced lung toxicity. Radiother Oncol 2009;91(3):421–6.
17.Lind PA, Marks LB, Jamieson TA, Carter DL, Vredenburgh JJ, Folz RJ, et al. Predictors for pneumonitis during locoregional radiotherapy in high-risk patients with breast carcinoma treated with high- -dose chemotherapy and stem-cell rescue. Cancer 2002;94(11):2821–9.
18.Chen S, Zhou S, Zhang J, Yin FF, Marks LB, Das SK. A neural network model to predict lung radiation-induced pneumonitis. Med Phys 2007;34(9):3420–7.
19.Kim H, Lussier YA, Noh OK, Li H, Oh YT, Heo J. Prognostic implication of pulmonary function at the beginning of postoperative radiotherapy in non-small cell lung cancer. Radiother Oncol 2014;113(3):374–8.